The groundbreaking success of the copyright undeniably transformed the pharmaceutical landscape, but betting in companies strongly reliant on off-patent versions presents a complex picture. While early profits were substantial, the expiration of patents and the emergence of discounted alternatives have weakened the customer base. Consequently, a th